INSM — INSMED Inc
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1104506 ·
Last close
$121.86
Market Cap
$26.73B
52W High
$212.75
52W Low
$90.39
ADV30
3,443,297
Next earnings
2026-10-29
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 524,428,000 | 446,213,000 | -81,829,000 | -100,319,000 | 2,226,056,000 | 396,563,000 | 1,499,842,000 |
| Jun 2026 | 425,486,000 | 358,274,000 | -101,308,000 | -13,242,000 | 2,102,565,000 | 544,765,000 | 1,345,071,000 |
| Mar 2026 | 305,964,000 | 258,544,000 | -200,281,000 | -163,563,000 | 2,075,863,000 | 582,188,000 | 1,371,011,000 |
| Dec 2025 | 263,843,000 | 219,623,000 | -249,708,000 | -328,485,000 | 2,264,558,000 | 510,445,000 | 1,525,582,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-595,622,000
Investing CF
$543,796,000
Financing CF
$114,189,000
CapEx
$-31,953,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.82
As of
2026-11-01
Balance + Analyst (yfinance extras)
Retained Earnings
$-5,913,816,000
Inventory
$163,946,000
Receivables
$259,270,000
ST Investments
$750,063,000
EBIT TTM
$-522,361,000
Pretax Income TTM
$-598,058,000
Interest Exp TTM
$75,697,000
Analysts
22
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,519,720,960
EBITDA
$-611,032,000
Free Cash Flow
$-456,756,256
Enterprise Value
$24,282,144,768
Total Cash
$1,146,626,048
Total Debt
$730,936,000
Shares Out
219,380,309
Trailing EPS
$-4.10
Book Value
$3.31
ROE
-72.5%
ROA
-17.3%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 606,423,000 | -994,776,000 | -1,276,775,000 | 2,264,558,000 | 1,525,582,000 | 738,976,000 | -935,014,000 |
| Dec 2024 | 363,707,000 | -786,570,000 | -913,772,000 | 2,025,231,000 | 1,739,852,000 | 285,379,000 | -683,882,000 |
| Dec 2023 | 305,208,000 | -680,929,000 | -749,567,000 | 1,329,837,000 | 1,661,760,000 | -331,923,000 | -536,247,000 |
| Dec 2022 | 245,358,000 | -478,123,000 | -481,534,000 | 1,656,435,000 | 1,568,484,000 | 87,951,000 | -400,439,000 |
TTM Snapshot
Revenues TTM
$1,137,635,000
NetIncome TTM
$-875,311,000
OpCashFlow TTM
—
Assets (Latest)
$2,102,565,000
Forward EPS
$0.75
Max Pain — expiry 2027-01-15
max pain strike: $100.00 · spot: $119.80 · call oi: 44,866 · put oi: 16,317
Expected Move to 2027-01-15:
±$20.75
(17.32%) —
implied range
$99.05 –
$140.55
· ATM straddle on $120.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ROIV | Roivant Sciences Ltd. | $28.05B | $38.71 | — |
| UTHR | UNITED THERAPEUTICS Corp | $24.88B | $584.10 | — |
| VTRS | Viatris Inc | $23.45B | $20.45 | — |
| RPRX | Royalty Pharma plc | $30.58B | $68.68 | — |
| GMAB | GENMAB A/S | $31.95B | $51.96 | — |
News headlines (Yahoo Finance, 1h cache)
Insmed Sees BRINSUPRI Reaching $7 Billion in Peak Sales, Expects Cash-Flow Positive Year Ahead
2026-11-17 07:12 · Yahoo
The Zacks Analyst Blog Highlights TG Therapeutics, BioCryst, Insmed and Madrigal
2026-11-11 06:36 · Yahoo
Nanoscope Therapeutics Appoints Ophthalmology and Rare Disease Regulatory Leader Damon Daulerio as Executive Director of Regulatory Affairs
2026-11-05 12:03 · Yahoo
Insmed to Present at November and December 2026 Investor Conferences
2026-11-04 12:00 · Yahoo
Insmed (INSM) Lifts Guidance After Earnings As Fair Value Debate Heats Up
2026-10-31 16:09 · Yahoo
Insmed (INSM) Begins BRINSUPRI Sales In Japan
2026-10-31 01:17 · Yahoo
INSM Q3 Earnings Miss, Stock Soars on Sales Beat & Raised Guidance
2026-10-30 13:29 · Yahoo
Insmed Incorporated Q3 2026 Earnings Call Summary
2026-10-30 12:30 · Yahoo
Why Did Insmed Stock Jump?
2026-10-30 11:15 · Yahoo
Insmed Soars 12% on $400 Million Brinsupri Quarter as U.S. Launch “Continues to Exceed Expectations”
2026-10-29 18:40 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.